Sun Pharmaceutical

Sun Pharmaceutical Industries

Type	Public
Traded as	:  : SUNPHARMA
Industry	Pharmaceuticals
Founded	1983
Founder	Dilip Shanghvi
Headquarters	Mumbai, Maharashtra, India
Key people	Dilip Shanghvi (Managing Director)
Products	Pharmaceuticals, generic drugs
Revenue	₹26,628 crore (US$4.0 billion) (2015)
Operating income	₹7,611 crore (US$1.1 billion) (2015)
Net income	₹3,891 crore (US$580 million) (2015)
Total assets	₹15,500 crore (US$2.3 billion) (2015)
Number of employees	52,700 (March 2016)
Website	www.sunpharma.com

Sun Pharmaceutical Industries Limited (: SUNPHARMA, : ) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. The company offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It also provides APIs such as warfarin, carbamazepine, etodolac, and clorazepate, as well as anticancers, steroids, peptides, sex hormones, and controlled substances.

Sun Pharmaceuticals was established by Mr. Dilip Shanghvi in 1983 in Vapi with five products to treat psychiatry ailments. Cardiology products were introduced in 1987 followed by gastroenterology products in 1989. Today it is the largest chronic prescription company in India and a market leader in psychiatry, neurology, cardiology, orthopedics, ophthalmology, gastroenterology and nephrology.

The 2014 acquisition of Ranbaxy has made the company the largest pharma company in India, the largest Indian pharma company in the US, and the 5th largest specialty generic company globally.

Over 72% of Sun Pharma sales are from markets outside India, primarily in the US. The US is the single largest market, accounting for about 50% turnover; in all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is across 26 locations, including plants in the US, Canada, Brazil, Mexico and Israel. In the US, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.S. Food and Drug Administration (FDA).